I would personally temper my expectations here a little on near term profitability.
Do we know which form of profitability that the company is referring to? I prefer NPAT because it is what is available to shareholders. Companies however typically prefer EBITDA because it is easier to generate.
EBITDA breakeven is possible on a monthly basis towards the end of the calendar year but NPAT breakeven looks like it is futher six months away to me and will require maybe up to $35m of revenue to achieve.
If I had to guess I would say we are probably looking at a $3-4m NPAT loss in the second half of FY24, versus a $5.6m loss in the first half.
The good news for the patient is that if/when it becomes apparent that NPAT profitability is guaranteed then I think we can see the big re-rate from 2x sales to 5x sales.
- Forums
- ASX - By Stock
- Nova Eye Medical (EYE) Discussion
I would personally temper my expectations here a little on near...
-
- There are more pages in this discussion • 708 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
SKS
SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne
Add EYE (ASX) to my watchlist
(20min delay)
|
|||||
Last
26.5¢ |
Change
0.010(3.92%) |
Mkt cap ! $60.63M |
Open | High | Low | Value | Volume |
26.0¢ | 27.5¢ | 26.0¢ | $318.2K | 1.199M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 40000 | 26.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
27.0¢ | 126253 | 10 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 40000 | 0.265 |
10 | 344871 | 0.260 |
8 | 286686 | 0.255 |
3 | 122050 | 0.250 |
2 | 40569 | 0.245 |
Price($) | Vol. | No. |
---|---|---|
0.270 | 126253 | 10 |
0.275 | 177785 | 4 |
0.280 | 314218 | 7 |
0.285 | 100000 | 1 |
0.290 | 170250 | 3 |
Last trade - 15.14pm 12/07/2024 (20 minute delay) ? |
Featured News
EYE (ASX) Chart |